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Abstract
Background: Timely HIV testing and initiation of antiretroviral therapy are two major determinants of survival for
HIV-infected individuals. Our study aimed to explore the trend of late HIV/AIDS diagnoses and to assess the factors
associated with these late diagnoses in China between 2006 and 2014.
Methods: We used data from the Chinese Comprehensive Response Information Management System of HIV/AIDS
(CRIMS). All individuals who tested positive for HIV between 2006 and 2014 in China and were at least 15 years of
age were included. A late diagnosis was defined as an instance in which an individual was diagnosed as having
AIDS or WHO stage 3 or 4 HIV/AIDS, or had a CD4 cell count less than 200 cells/mm3 at the time of diagnosis.
Results: Among the 528,234 individuals (≥15 years old) newly diagnosed with HIV between 2006 and 2014, 179,700
(34.0%) people were considered to have received late diagnoses. The late diagnosis rate decreased from 33.9% in 2006
to 29.7% in 2014 (P < 0.01). Late diagnoses were more likely to be found among those who were 45–54 years old
(adjusted odds ratio [aOR]: 3.25, 95% confidence interval [CI]: 3.17–3.34) or 55+ years old (OR: 2.94, 95% CI: 2.86–3.02),
male (aOR: 1.15, 95% CI: 1.13,1.17), employed as a farmer or rural laborer (aOR: 1.13, 95% CI: 1.11–1.14), infected through
blood or plasma transfusion (aOR: 4.18, 95% CI: 4.02, 4.35), diagnosed at hospitals (OR: 1.17, 95% CI: 1.15, 1.19), of Han
ethnicity (aOR: 1.30, 95% CI: 1.28, 1.32), and married (OR: 1.12, 95% CI: 1.11,1.13). Of those people living with HIV (PLHIV)
who received late diagnoses, 7.4%(8637) and 46.1%(28,462) ultimately died with or without receiving antiretroviral
therapy within a year of diagnosis, respectively.
Conclusion: A large proportion of individuals with HIV/AIDS receive late diagnoses, and this proportion has witnessed
a slight decline in recent years. Expanded testing is needed to increase early HIV diagnosis and antiretroviral therapy
should be recommended to all diagnosed individuals as early as possible to reduce AIDS-related death.
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Background
The introduction and expansion of highly active anti-
retroviral therapy (HAART) has proven to be one of the
most remarkable public health measures in reducing the
morbidity and mortality caused by the Human Immuno-
deficiency Virus (HIV) [1–4]. UNAIDS sets an ambitious
treatment target to help end the AIDS epidemic: By
2020, 90% of all people living with HIV know their HIV
status, 90% of people with diagnosed HIV receive
antiretroviral therapy (ART) and 90% of all people on
HIV treatment achieve viral suppression [5]. However,
delayed testing as well as stigma and discrimination
against infected individuals places them at risk of receiv-
ing delayed antiretroviral therapy [6].
Early detection of HIV infection is a critical factor in
controlling the spread of HIV [7]. Timely ART is associ-
ated with a better prognosis among HIV-infected indi-
viduals and lower rates of disease progression [8].
Prompt linkages with health care systems at the start of
ART yields the maximum benefits of HIV medical treat-
ment for people living with HIV (PLHIV) [9] while de-
creasing the sexual transmission rate of HIV [10–13]. A
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late diagnosis is detrimental to both the individual in-
fected with HIV and the community for two reasons.
First, in the absence of timely initiation of ART, the ma-
jority of patients will suffer the deleterious effects of
HIV infection due to the gradual failure of the immune
system, ranging from infection by opportunistic diseases
to even death. Second, the propensity for HIV transmis-
sion by untested and hence unaware PLHIV is greater
[14, 15] than for those made aware of their HIV status.
Developed countries such as the USA, Canada, and
the European Union have been successful in addressing
some of the key operational factors hindering the effect-
ive management of diseases affecting PLHIV [16–21].
However, it is estimated that 30% of PLHIV in the Euro-
pean Union [9] remain undiagnosed, while evidence
from the United States suggests that 25% of the undiag-
nosed population is responsible for the transmission of
new HIV infections in 54% of cases [7, 22].
The proportion of those who received late diagnoses
in industrialized countries is most often reported at be-
tween 25 and 45% of all newly HIV-diagnosed cases
[23]. Though the largest proportion of undiagnosed
PLHIV resides in developing countries, little research
describing their characteristics has been conducted in
these settings. In China, HIV voluntary counseling and
testing (VCT) is free and can be widely accessed in
urban areas. However, this free testing strategy has not
been able to prevent a large proportion of cases of late
HIV diagnosis for several reasons [24]. Incomplete HIV
screening among STD patients in China has been cited
as one important cause of missed opportunities for HIV
testing [25].
Our study aimed to identify characteristics and trends
of cases of late HIV/AIDS diagnosis, and to assess the
factors associated with late diagnosis, early mortality,
and ART initiation in China between 2006 and 2014.
Methods
Data sources and definitions
In China, all newly diagnosed HIV/AIDS cases and all
recipients of free ART are registered into the Chinese
Comprehensive Response Information Management Sys-
tem of HIV/AIDS (CRIMS). CRIMS is managed by the
National Centre for AIDS/STD Control and Prevention
(NCAIDS) of the Chinese Centre for Disease Control
and Prevention (China CDC) and includes the National
Case Reporting Database (NCRD) and the National Free
Antiretroviral Therapy Database (NFATD). The NCRD
collects data on newly diagnosed HIV/AIDS cases, in-
cluding demographic characteristics, route of infection,
site of HIV diagnosis or blood sample source, date of
diagnosis, laboratory test results with corresponding test
date, and date of death. These cases are followed up
every 6 months. During each follow-up, CD4 cell count,
counseling and behavior intervention, and other referral
services are performed. The NCRD also collects add-
itional data during each follow-up visit, including
changes in demographic information, disease stage, CD4
cell count, information on behavioral determinants, and
details of ART. The NFATD includes all cases that meet
the national treatment criteria and have received free
treatment. In China, the national criteria for treatment is
a CD4 cell count of less than 350 cells/mm3 (as of 2009)
and later, of less than 500 cells/mm3 (as of 2014), or be-
ing reported as having AIDS, or having WHO stage 3 or
4 HIV/AIDS and having been referred for ART [26–29].
Information on the individual’s drug regiment during
each follow-up visit is recorded and then uploaded to
the CRIMS.
A detailed description of the NCRD and NFATD has
been published elsewhere [26], including a discussion of
quality control of lab work [28]. There have been several
important ART studies based on the data from these two
systems in recent years [27–29]. In this study, we up-
dated the results in continuation with earlier findings
from the cohort study [27]. We included all newly diag-
nosed HIV/AIDS cases between 1 January 2006 and 31
December 2014 in mainland China involving individuals
aged 15 years and over and excluded individuals who
could not be located by local CDCs during follow-up
visits.
There were several explanations for the term “late
diagnosis” [30–32]. In this study, we classified a case as
a “late diagnosis” if an individual was reported as 1) hav-
ing been diagnosed with AIDS or 2) having been diag-
nosed with WHO stage 3 or 4 HIV/AIDS, or 3) having
an initial CD4 cell count of less than 200/mm3 within
one year after the date of HIV diagnosis. Early mortality
was defined as death from AIDS-related causes within
one year of an HIV/AIDS diagnosis. Cases without a
death certificate or without being lost to follow-up as of
31 December 2014, were assumed to be alive. Cases who
died of overdose drug use or suicide were excluded.
We defined preventable early mortality as the esti-
mated number of AIDS-related deaths within one year
of diagnosis attributed to late diagnosis. The number of
preventable early mortality equals to the number of ob-
served AIDS-related deaths within one year of diagnosis
minus the estimated number of AIDS-related deaths
within one year of diagnosis according to the early mor-
tality rate of those who received timely HIV diagnoses.
Statistical analysis
We used SAS software (version 9.4; SAS Institute; Cary,
NC) for data analysis and MapInfo Professional software
(version 15.0; Pitney Bowes; USA) for maps creation.
Descriptive analysis was done for late diagnoses across
all cases, including gender, age at HIV diagnosis, marital
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status, education level, route of transmission, ethnic
group, and screening sites. Screening sites were catego-
rized into three groups: VCT sites, hospitals, and deten-
tion centers. Transmission routes were classified into
five groups: heterosexual, homosexual, injection drug
use, sexual contact and injection drug use, and former
paid blood/plasma donation. Odds ratio (OR) was used
to assess the factors associated with late diagnosis by
means of univariate and multivariate logistic regression
models. Variables for which P values were less than 0.05
were considered to be statistically significant.
Results
A total of 563,961 individuals were newly diagnosed
with HIV infection in mainland China during the
period between 1 January 2006 and 31 December
2014. A total of 35,727 subjects were excluded from
this analysis, as 28,544 cases could not be traced after
the initial positive tests and 7183 cases concerned in-
dividuals were under 15 years of age (Fig. 1). Among
the remaining 528,234 individuals, the majority were
male (72.7%), married (50.2%), had attained a middle
school level education or higher (60.8%), heterosexual
(63.2%), and belonged to the Han ethnic group
(74.6%). Most were diagnosed a t hospitals (44.7%)
and VCT sites (28.4%) (Table 1).
In this cohort, 179,700 (34.0%) individuals newly diag-
nosed with HIV infection were classified as “late diagno-
sis” cases in accordance with the definition. The late
diagnosis rate decreased from 33.9% in 2006 to 29.7% in
2014 (P < 0.01) (Fig. 2). The proportion of cases of late
diagnosis were more than 55 % among four provinces in
2006, three provinces in 2010 and none in 2014 (Fig. 3).
The proportion of cases of late diagnosis was greater
among those who were over 45 years old, married,
farmers or rural laborers, and of Han ethnicity, infected
through heterosexual transmission or former blood/
plasma transfusion, diagnosed at hospitals, (Table 1). In
addition, our results indicated that cases of late diagnosis
increased with an increase in age in all calendar years
during the study period.
As per our results, factors independently associated
with an increased likelihood of late diagnosis were be-
ing male (aOR: 1.15, 95% CI: 1.13–1.17), being in an
older age group (aOR: 3.25, 95% CI: 3.17–3.34 for
45–54 years old; aOR: 2.94, 95% CI: 2.86–3.02 for 55
+ years old), having acquired HIV infection through
former blood or plasma transfusion (aOR: 4.18, 95%
CI: 4.02–4.35), being of Han ethnicity (aOR: 1.30,
95% CI: 1.28–1.32), being married or living with a
partner (aOR: 1.15, 95% CI: 1.13–1.17), being farmers
(aOR: 1.13, 95% CI: 1.11–1.14), and being tested at
hospitals (aOR: 1.17, 95% CI: 1.15–1.19).
Around 52.0% of newly diagnosed cases (274,552) had
their CD4 cell count results available within one month
of HIV diagnosis (Table 2). This proportion increased
from 19.0% in 2006 to 65.8% in 2014. Furthermore, this
proportion was the lowest (29.7%) among those who
were infected through injection drug use. Those who
were diagnosed at VCT clinics received a timely (within
one month) CD4 cell count testing of 60.9%.
Our results indicate that 76.5% (404,000) of newly
HIV diagnosed individuals received testing for CD4 cell
count within one year of HIV diagnosis (Table 2). Of
these individuals, 32.4% (131,095) had a CD4 cell count
less than 200 cells/mm3. The proportion with a CD4 cell
count test administered within one year increased during
the study period from 35.1% in 2006 to 88.3% in 2014,
and the proportion of CD4 cell count less than 200
cells/mm3 decreased from 42.7% in 2006 to 29.7% in
2014. Those infected through former blood or plasma
transfusion witnessed a high proportion of CD4 cell
count less than 200 cells/mm3. The proportion of CD4
cell count less than 200 cells/mm3 increased with age,
from 13.3% in 15–24 age group to 44.8% in 55+ age
group.
Early mortality and access to ART
Of the 179,700 individuals who received late diagnoses,
excluding 1404 individuals who died of overdose drug
use or suicide, the proportions receiving ART within
one month of diagnosis and within one year of diagnosis
were 30.1 and 65.4%, respectively. The percentage of the
individuals who received late diagnoses, received ART,
and died within one month of diagnosis was 0.51%. The
percentage of the individuals who received late diagno-
ses, received ART, and died within one year of diagnosis
was 7.4% (Table 3). 17.4% of individuals who received
late diagnoses but did not receive ART died within one
month of diagnosis, and 46.1% of those who received
late diagnoses without ART died within one year of diag-
nosis. Upon further analysis, the early mortality was
20.8% (37,099/178,296) among those who received late
diagnoses and 9.6% (32,626/341,072) among those with
timely diagnoses (P < 0.01).
Among PLHIV who received late diagnoses, the pro-
portion experiencing early mortality declined annually
from 2006 to 2014 with an increase in the proportion re-
ceiving ART (Table 4). The early mortality rates for indi-
viduals who received late diagnoses were 29.5% in 2006
and 14.5% in 2014. At the same time, the treatment
coverage rates for these individuals within one year of
diagnosis were 39.5% in 2006 and 73.9% in 2014. The
treatment coverage rate for those who reported having
had sex with men was highest (82.8%) (p < 0.01), there-
fore, this group also experienced the lowest rate of early
mortality (8.0%) (Table 4).
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Estimation of preventable early mortality
Early mortality among those who received timely HIV
diagnoses was 9.6%. Basing our assumptions of previ-
ous research [30–32], we presumed in our study that
1) early mortality would be reduced to 9.6% if there
were no late diagnoses; 2) there would be no effect
on deaths occurring more than a year after diagnosis;
and 3) there would no other competing risks. Based
on these conjectures, only 17,116 deaths would have
been expected from 2006 to 2014 within a year of
diagnosis if the diagnosis was timely. That is, 19,983
deaths would have been avoided during this period,
compared to the 37,099 deaths actually observed
among the group with late HIV diagnoses. Therefore,
Fig. 1 Study profile
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Table 1 Demographic Characteristics and factors associated with late diagnosis in China between 2006 and 2014 (N = 528,234)
Categories Newly diagnosed
(age > 14 years old)
n (%) of Late
diagnosis
Unadjusted OR
(95%CI)
Adjusted OR
(95%CI)
Total 528,234 179,700(34.0) _ _
Year of HIV diagnosis
2006 26,027 8823(33.9) Ref. Ref.
2007 32,538 11,427(35.1) 1.06(1.02–1.09) 1.04(1.00–1.08)
2008 40,690 13,734(33.8) 0.99(0.96–1.03) 0.93(0.89–0.96)
2009 48,163 17,073(35.4) 1.07(1.04–1.11) 0.99(0.95–1.02)
2010 53,375 19,700(36.9) 1.14(1.11–1.18) 0.99(0.96–1.03)
2011 67,256 23,944(35.6) 1.08(1.05–1.11) 0.89(0.86–0.92)
2012 76,716 26,598(34.7) 1.04(1.01–1.07) 0.84(0.81–0.87)
2013 85,518 29,291(34.3) 1.02(0.99–1.05) 0.82(0.79–0.85)
2014 97,951 29,110(29.7) 0.83(0.80–0.85) 0.65(0.63–0.68)
Sex
Female 144,013 49,803(34.6) Ref. Ref.
Male 384,221 129,897(33.8) 0.97(0.95–0.98) 1.15(1.13–1.17)
Age groups(years)
15–24 74,796 12,174(16.3) Ref. Ref.
25–34 163,089 44,161(27.1) 1.91(1.87–1.95) 187(1.82–1.91)
35–44 132,507 51,750(39.1) 3.30(3.22–3.37) 2.78(2.72–2.85)
45–54 70,158 32,262(46.0) 4.38(4.27–4.49) 3.25(3.17–3.34)
55+ 87,684 39,353(44.9) 4.19(4.09–4.29) 2.94(2.86–3.02)
Marital status
Single, divorced, or widowed 256,895 74,319(28.9) Ref. Ref.
Married or lives with partner 264,977 104,087(39.3) 1.59(1.57–1.61) 1.12(1.11–1.13)
Education
Middle school or more 331,210 111,091(33.5) Ref. Ref.
Primary school or less 191,811 67,212(35.0) 1.07(1.06–1.08) 0.87(0.86–0.89)
Occupation
Other 278,138 84,141(30.3) Ref. Ref.
Farmer or rural laborer 250,096 95,559(38.2) 1.43(1.41–1.44) 1.13(1.11–1.14)
Ethnic group
Other 134,406 35,356(26.3) Ref. Ref.
Han 393,828 144,344(36.7) 1.62(1.60–1.64) 1.30(1.28–1.32)
Route of HIV infection
Heterosexual 333,753 126,658(37.9) Ref. Ref.
Homosexual 85,252 20,891(24.5) 0.53(0.52–0.54) 0.71(0.70–0.73)
Injection drug use 73,834 14,111(19.1) 0.39(0.38–0.39) 0.63(0.61–0.64)
Sexual contact and injection
drug use
5257 1147(21.8) 0.46(0.43–0.49) 0.71(0.66–0.76)
Blood or plasma transfusion 16,767 12,910(77.0) 5.47(5.28–5.68) 4.18(4.02–4.35)
Sites of diagnosis
VCT centers 150,157 54,260(36.1) Ref. Ref.
Hospitals 236,047 97,220(41.2) 1.24(1.22–1.25) 1.17(1.15–1.19)
Detention centers 43,231 5087(11.8) 0.24(0.23–0.24) 0.35(0.34–0.37)
others 98,799 23,133(23.4) 0.54(0.53–0.55) 0.59(0.58–0.61)
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the current burden of early mortality would be re-
duced by about 53.9%.
Discussion
It has been thirty years since HIV testing first became
available [33]. Despite the decades of availability of test-
ing, it was estimated that at least one-fourth of PLHIV
worldwide were unaware of their infection [24, 34–39],
and that this ratio could be even higher in China
[24].Our results indicate that promoting timely diagnosis
and treatment provided a survival advantage to PLHIV,
and that almost 54% of deaths that occurred within one
year of HIV diagnosis could thus be prevented. Our
study expanded upon the existing literature [16, 32, 37,
40, 41] by evaluating late diagnoses among all HIV cases
identified between 2006 and 2014 in China, by assessing
and mapping the trend of late diagnosis over time and
by evaluating factors associated with late diagnosis
among HIV cases in China.
In our study, 34.0% of HIV cases were considered
to have received late diagnoses between 2006 and
2014. The late diagnosis rate fluctuated from 2006 to
2014, but slightly decreased from 36.9% in 2010 to
29.7% in 2014 (P < 0.01). This declining could be due
to the implementation of the provider-initiated HIV
testing and counseling (PITC) strategy since 2009.
After the initiating of PITC, the HIV testing was signifi-
cantly scaled up in most of provinces in China [37, 38,
42]. The scaling up of HIV self-testing in China could be
another reason for this phenomenon. For example, around
30% of MSM in China self-reported that they ever
self-tested in 2016 [36].
The propensity to receive late HIV testing was greater
for older people, those who had acquired HIV infection
through former blood or plasma transfusion or hetero-
sexual behaviors, individuals of Han ethnicity, married
individuals, and farmers. These results are consistent
with the findings of previous studies [31, 43], with the
exception of some studies in the U.S. indicated that
younger people was more likely to receive late testing
[44, 45]. In recent years, spouses’ and regular partners’
testing was scaled up in China, because of a series of na-
tional and provincial laws, regulations, and policy
initiatives.
Table 1 Demographic Characteristics and factors associated with late diagnosis in China between 2006 and 2014 (N = 528,234)
(Continued)
Categories Newly diagnosed
(age > 14 years old)
n (%) of Late
diagnosis
Unadjusted OR
(95%CI)
Adjusted OR
(95%CI)
Migrant populationa
No 402,155 143,160(35.6) Ref. Ref.
Yes 126,079 36,540(29.0) 0.74(0.73–0.75) 0.94(0.93–0.96)
aMigrant population: people migrated from one county to another county and stay there for at least six months
Fig. 2 Proportions of individuals diagnosed late in different calendar years of diagnosis (X axis: calendar year of diagnosis; Y axis: proportion of
late diagnosis)
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Fig. 3 Proportions of individuals diagnosed late in different calendar years of diagnosis among 31 provinces in China (a: year of 2006, b: year of
2010, c: year of 2014)
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The majority of late diagnoses occurred among those
who were infected with HIV through heterosexual be-
haviors. It indicated that there might have been a pro-
longed period of transmission risk to their sexual
partners. Strategies, promoting rapid HIV testing at pri-
mary level of health institutions, promoting HIV
self-testing, and increasing collaboration with commu-
nity based organizations (CBOs), should be further im-
plemented. Also, the risk of late diagnosis was
significantly higher for those who were infected through
former blood or plasma transfusion. Illegal paid plasma
donation was prominent in central China in the 1990s
and resulted in the infection of the majority of donors
with the HIV virus [26, 46, 47]. Most of these PLHIV
did not seek testing due to societal discrimination and
stigma against HIV. As a result, they were diagnosed
with HIV only after they experienced symptoms. Most
of these people are located in four provinces in central
China, as shown in Fig. 3.
However, the proportion of late testing has decreased
among men who have sex with men (MSM) and
injection drug users in recent years. This finding may
have been due to ongoing intervention programs that
promoted testing in these high risk groups [48, 49], such
as methadone maintenance treatment (MMT) for injec-
tion drug users and free HIV testing for MSM provided
by CBOs and VCT clinics. Similar results have been
found in other studies [45].
Individuals who present at an advanced stage of im-
munosuppression are at high risk of clinical events and
death and are more likely to have a poor response when
they start ART [50, 51]. The proportion of people receiv-
ing late diagnoses among newly diagnosed individuals
remained at more than 30% between 2006 and 2013.
However, this proportion has been in decline since 2010.
In an era where effective and free testing and free treat-
ment options are available in China, it is alarming that
there is a substantial proportion of people were late di-
agnosed, and they are at higher risk of early death. A
records-based retrospective cohort study in China
found that the highest mortality rates for AIDS-related
death and all-cause death were found in the first year
Table 2 Initial CD4 cell counts after diagnosed of HIV newly diagnosed individuals in China between 2006 and 2014 (N = 528,234)
Characteristic Newly diagnosed
(age > 14 years old)
Initial CD4 cell count
within one month
Initial CD4 cell count
within one year
Initial CD4 cell counts < 200
cell/ul within one year
n % n % n %
Year of HIV diagnosis
2006 26,027 4950 19.0 9129 35.1 3901 42.7
2007 32,538 8856 27.2 15,621 48.0 6282 40.2
2008 40,690 14,475 35.6 23,979 58.9 8491 35.4
2009 48,163 20,327 42.2 32,083 66.6 11,321 35.3
2010 53,375 25,110 47.0 40,073 75.1 13,511 33.7
2011 67,256 35,950 53.5 54,378 80.9 18,002 33.1
2012 76,716 45,550 59.4 66,064 86.1 20,444 30.9
2013 85,518 54,931 64.2 76,191 89.1 23,474 30.8
2014 97,951 64,403 65.8 86,482 88.3 25,669 29.7
Route of HIV infection
Heterosexual 333,753 183,602 55.0 264,332 79.2 96,527 36.5
Homosexual 85,252 57,299 67.2 78,895 92.5 15,515 19.7
Injection drug use 73,834 21,958 29.7 40,713 55.1 9168 22.5
Sexual contact and
injection drug use
5257 1760 33.5 3257 62.0 777 23.9
Blood or plasma
transfusion
16,767 7006 41.8 11,833 70.6 7142 60.4
Sites of diagnosis
VCT centers 150,157 91,425 60.9 124,603 83.0 39,141 31.4
Hospitals 236,047 118,702 50.3 176,834 74.9 73,114 41.3
Detention centers 43,231 12,397 28.7 23,395 54.1 3196 13.7
others 98,799 52,028 52.7 79,168 80.1 15,644 19.8
Total 528,234 274,552 52.0 404,000 76.5 131,095 32.4
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of follow up after HIV diagnosis [52]. This phenomenon
could be explained by the fact that about half of the par-
ticipating cases had already progressed to AIDS before be-
ing identified, progression to AIDS was one of the
strongest risk factors for AIDS-related death, with an aHR
of 7.42 [52].
Individuals who present at an advanced stage of im-
munosuppression are at high risk of AIDS related dis-
eases and death as well as more likely to have a poorer
response to ART [36, 53]. Both HIV testing and ART
have been free for PLHIV in China since 2003 [54]. In
spite of this policy, our results indicate that as many as
30% of all newly diagnosed individuals received late
diagnoses. Shortening the time from infection to meas-
urement of CD4 cell counts could be an important win-
dow for early treatment. We infer that the time from
infection to CD4 measurement is a useful indicator for
monitoring delays in access to HIV medical care among
newly diagnosed PLHIV [55]. In our analysis, 52.0% of
newly diagnosed individuals had their CD4 cell counts
available within one month of HIV diagnosis. This pro-
portion increased from 19.0% in 2006 to 65.8% in 2014.
Table 3 Early mortality among late diagnosed individuals with or without ART, by month (N = 178,296)
Duration of time
from diagnosis
Initial CD4
counts
ON ART NO ART
N No. of deatha % of death Na No. of deatha % of death
One month 0–49 33,897 325 0.96 15,344 2449 15.96
50–99 19,220 63 0.33 7153 516 7.21
100–199 37,747 44 0.12 13,934 330 2.37
200–349 17,685 14 0.08 6718 81 1.21
350–499 5135 3 0.06 3301 32 0.97
500- 2041 0 0.00 1977 10 0.51
No CD4 test 848 142 16.75 13,296 7316 55.02
subtotal 116,573 591 0.51 61,723 10,734 17.39
Three months 0–49 33,897 1551 4.58 15,344 5705 37.18
50–99 19,220 390 2.03 7153 1399 19.56
100–199 37,747 283 0.75 13,934 1000 7.18
200–349 17,685 61 0.34 6718 201 2.99
350–499 5135 15 0.29 3301 77 2.33
500- 2041 3 0.15 1977 34 1.72
No CD4 test 848 398 46.93 13,296 9674 72.76
subtotal 116,573 2701 2.32 61,723 18,090 29.31
Six months 0–49 33,897 2950 8.70 15,344 7963 51.90
50–99 19,220 880 4.58 7153 2253 31.50
100–199 37,747 678 1.80 13,934 1684 12.09
200–349 17,685 147 0.83 6718 359 5.34
350–499 5135 39 0.76 3301 157 4.76
500- 2041 14 0.69 1977 70 3.54
No CD4 test 848 560 66.04 13,296 10,838 81.51
subtotal 116,573 5268 4.52 61,723 23,324 37.79
Twelve months 0–49 33,897 4521 13.34 15,344 9796 63.84
50–99 19,220 1520 7.91 7153 3100 43.34
100–199 37,747 1385 3.67 13,934 2654 19.05
200–349 17,685 361 2.04 6718 628 9.35
350–499 5135 107 2.08 3301 307 9.30
500- 2041 53 2.60 1977 141 7.13
No CD4 test 848 690 81.37 13,296 11,836 89.02
subtotal 116,573 8637 7.41 61,723 28,462 46.11
aThose who died of overdose drug use or suicide were excluded
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Table 4 Access to ART and early mortality among late diagnosis individuals within one year of diagnosis between 2006 and 2014
(N=178,296)
Characteristics Late diagnosis
(age>14 years old)*
N (% of access to
ART within one month)
N (% of access to
ART within one year)
N (% of died after
receiving ART)
χ2 P-value b
Year of HIV diagnosis 141.52 <0.01
2006 8675 1436(16.6) 3429(39.5) 267(7.8)
2007 11252 2105(18.7) 5126(45.6) 341(6.7)
2008 13535 3051(22.5) 7387(54.6) 568(7.7)
2009 16874 3906(23.1) 9527(56.5) 621(6.5)
2010 19532 4498(23.0) 12021(61.5) 679(5.6)
2011 23741 6383(26.9) 16355(68.9) 1076(6.6)
2012 26445 8524(32.2) 19038(72.0) 1495(7.9)
2013 29192 11068(37.9) 22212(76.1) 1897(8.5)
2014 29050 12668(43.6) 21478(73.9) 1693(7.9)
Sex 137.54 <0.01
Female 49561 15132(30.5) 32806(66.2) 1959(6.0)
Male 128735 38507(29.9) 83767(65.1) 6678(8.0)
Age group (years) 871.48 <0.01
15-24 12082 3107(25.7) 8305(68.7) 317(3.8)
25-34 43688 12146(27.8) 28734(65.8) 1436(5.0)
35-44 51244 15499(30.2) 33684(65.7) 2430(7.2)
45-54 32084 10846(33.8) 21947(68.4) 1832(8.3)
55+ 39198 12041(30.7) 23903(61.0) 2622(11.0)
Marital status 11.08 <0.01
Single, divorced, or widowed 73626 20957(28.5) 48061(65.3) 3411(7.1)
Married or lives with partner 103411 32483(31.4) 67970(65.7) 5177(7.6)
Education 488.54 <0.01
Middle school or more 110338 34898(31.6) 77177(69.9) 4792(6.2)
Primary school or less 66599 18585(27.9) 39012(58.6) 3826(9.8)
Occupation 663.26 <0.01
Other 83510 25305(30.3) 57787(69.2) 3130(5.4)
Farmer or rural laborer 94786 28334(29.9) 58786(62.0) 5507(9.4)
Ethnic group 16.57 <0.01
Others 34969 9013(25.8) 19866(56.8) 1335(6.7)
Han 143327 44626(31.1) 96707(67.5) 7302(7.6)
Route of HIV infection 622.49 <0.01
Heterosexual 126054 40124(31.8) 83978(66.6) 6547(7.8)
Homosexual 20832 6951(33.4) 17167(82.4) 646(3.8)
Injection drug use 13531 1955(14.4) 5809(42.9) 372(6.4)
Sexual contact and IDU 1102 245(22.2) 560(50.8) 31(5.5)
Blood or plasma transfusion 12841 3722(29.0) 7457(58.1) 917(12.3)
Sites of diagnosis 681.88 <0.01
VCT centers 53825 17809(33.1) 36452(67.7) 2346(6.4)
Hospitals 96608 29659(30.7) 62791(65.0) 5683(9.1)
Detention centers 4859 197(4.1) 1563(32.2) 62(4.0)
others 23004 5974(26.0) 15767(68.5) 546(3.5)
Tang et al. BMC Infectious Diseases  (2018) 18:272 Page 10 of 13
It is very important for late diagnosed individuals to
receive CD4 cell count testing immediately, so that
they can receive referrals for timely ART and thus re-
duce their risk of death. In our study, this proportion
of cases received ART within one month after the
diagnoses increased from 16.6% in 2006 to 43.6% in
2014. The average proportion of having CD4 counts
within one year was 76% from 2006 to 2014. The
causes of not having CD4 counts testing within one
year included death before having CD4 counts, lost to
follow up, and inconvenience to access to CD4 count
test. To shorten the time to CD4 cell count testing
and to improve access to regular testing and treat-
ment, efforts were taken in the past few years to dra-
matically improve referrals and integration of patient
tracking between the health facilities responsible for
patients follow up, CD4 cell count testing, and ART
delivery [56].
Our analysis suggests that groups at high risk of late
diagnosis should be targeted for appropriate public
health intervention and encouraged to seek earlier treat-
ment. Scaling up HIV testing is one of the important
strategies in implementing this goal. This strategy may
bring out a greater proportion of hidden individuals in-
fected with HIV [57]. Another strategy would be to con-
sider population-wide screening for HIV, such as for
patients in hospitals. In the U.S., the CDC recommends
routine HIV counseling and testing in healthcare settings
for patients aged 13–64 years, unless the local HIV
prevalence is known to be less than 0.1% [1].
There are some limitations to consider while interpret-
ing our findings. Firstly, 2.3% (12,352/528234) individ-
uals were lost to follow-up after HIV diagnoses, and
then CD4 cell counts data or having WHO stage 3 or 4
of them were not available at diagnosis. Thus, it is pos-
sible that some individuals with AIDS may have been
misclassified as having HIV. However, the resulting mis-
classification will be non-differential and might bias the
estimates towards the null, because the proportion of in-
dividuals misclassified does not depend on the individual
with respect to other variables on the analysis [58]. Sec-
ondly, our results couldn’t assess differences in mortality
in late diagnosed individuals who access to ART based
on ART regimen. It needs further research.
Conclusion
Even with these limitations, our results still indicate that
it is important to increase the accessibility of HIV testing
services. Routine testing for most individuals has been
recommended as a cost-effective strategy and efforts to
promote such testing should be developed [40, 53].
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ART within one month)
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N (% of died after
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